TauC3 Biologics
UK - LondonBiotechnology
Focus: Antibody targeting N- or C-terminus neoepitopes of toxic proteins in neurodegenerative diseases
TauC3 Biologics is a life sciences company focused on Antibody targeting N- or C-terminus neoepitopes of toxic proteins in neurodegenerative diseases.
Profile data last refreshed Yesterday
Open Jobs
0
Data completeness
0/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Open Jobs (0)
No open positions listed yet.
Interview Prep Quick Facts
Founded: 2022
Help build intelligence for TauC3 Biologics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.